Pharmacokinetics, Pharmacodynamics and Safety of Janagliflozin in Chinese Type 2 Diabetes Mellitus Patients with Renal Impairment

Zhao, HL; Zhao, ZR; He, K; Mi, NR; Lou, K; Dong, XL; Zhang, WY; Sun, JF; Hu, XY; Pang, SG; Cheng, H; Wen, Q

Wen, Q (通讯作者)，Shandong First Med Univ, Cent Hosp Affiliated, Dept Clin Res Ctr, 105 Jiefang Rd, Jinan 250013, Peoples R China.;Cheng, H (通讯作者)，Capital Med Univ, Beijing Anzhen Hosp, Dept Renal Div, 2 Anzhen St, Beijing 100029, Peoples R China.;Pang, SG (通讯作者)，Shandong First Med Univ, Cent Hosp Affiliated, Dept Endocrinol, 105 Jiefang Rd, Jinan 250013, Peoples R China.

CLINICAL PHARMACOKINETICS, 2023; 62 (8): 1093

Abstract

Background Janagliflozin is a novel sodium-glucose cotransport-2 inhibitor. Despite its remarkable effect in glycemic control, no systematic research ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索